The IDE submission is a binary catalyst — FDA acceptance could drive a significant re-rating, while rejection or clinical delays would accelerate the cash crunch. With only ~$3.9M cash and a $1M ELOC draw post-quarter, the company likely needs additional financing within 3-6 months. Monitor for FDA feedback on the IDE and any capital raise announcements.
Price Chart
Executive Summary
Glucotrack reported Q1 2026 results with a net loss of $4.3M, narrower than the $6.8M loss in Q1 2025, driven by a non-cash reduction in derivative liabilities. The key catalyst is the submission of its IDE application to the FDA for its implantable CBGM technology, targeting a U.S. clinical trial launch in 2H 2026. Cash runway extends into early Q3 2026, providing a narrow window before the next capital need.
Key Financial Metrics
Key Facts
- Net loss for Q1 2026 was $4.3M vs $6.8M in Q1 2025, a $2.5M improvement primarily from a non-cash change in derivative liabilities
- Cash and cash equivalents were $3.9M as of March 31, 2026, down from $7.4M at December 31, 2025
- Company submitted IDE application to FDA for its fully implantable CBGM technology
- Promissory note balance reduced from $3.6M to approximately $1.6M via stock-for-debt exchange
- Subsequent to quarter end, drew ~$1.0M under existing equity line of credit facility
- Shares outstanding increased from 910,688 at Dec 31, 2025 to 2,524,279 at March 31, 2026
- Cash runway expected into early Q3 2026, sufficient to initiate U.S. clinical trial
Financial Impact
Net loss improved by $2.5M YoY to $4.3M; cash burn of $4.1M from operations in Q1 2026
Risk Factors
- Cash runway only into early Q3 2026 — high risk of dilutive financing before clinical trial initiation
- IDE may not be approved by FDA, delaying or derailing U.S. clinical trial plans
- Share count more than doubled in Q1 2026 (910K to 2.5M shares), with further dilution from ELOC draws and warrant exercises likely
- Pre-revenue development-stage company with no approved products and history of operating losses
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-023202 |
| Document: form8-k.htm | 0001493152-26-023202 |
| Document: 0001493152-26-023202-index-headers.html | 0001493152-26-023202 |
| Document: 0001493152-26-023202-index.html | 0001493152-26-023202 |
| Document: 0001493152-26-023202.txt | 0001493152-26-023202 |
| 8-K Data (Synthetic) | 0001493152-26-023202 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | 8-K | $0.6081 | awaiting T+60 | — | — |
Oct 19, 2026 7d ago | 8-K | $0.6511 | awaiting T+60 | — | — |
Oct 13, 2026 12d ago | S-1/A | $0.8873 | awaiting T+60 | — | — |
Oct 13, 2026 13d ago | 425 | $0.8873 | awaiting T+60 | — | — |
Sep 28, 2026 27d ago | 8-K | $1.74 | awaiting T+60 | — | — |
Sep 24, 2026 4w ago | 424B5 | $1.82 | awaiting T+60 | — | — |
Sep 24, 2026 4w ago | 8-K | $1.82 | awaiting T+60 | — | — |
Sep 23, 2026 4w ago | 425 | $2.03 | awaiting T+60 | — | — |
Sep 23, 2026 4w ago | 8-K | $2.03 | awaiting T+60 | — | — |
Sep 18, 2026 5w ago | 8-K | $2.30 | awaiting T+60 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers